IGMS Stock Overview
A clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.48 |
| 52 Week High | US$22.50 |
| 52 Week Low | US$6.17 |
| Beta | 0.0055 |
| 1 Month Change | -21.01% |
| 3 Month Change | -55.08% |
| 1 Year Change | -3.86% |
| 3 Year Change | -73.55% |
| 5 Year Change | -83.92% |
| Change since IPO | -69.22% |
Recent News & Updates
Recent updates
We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08
IGM Biosciences: Waiting For Godot
Sep 18IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25Shareholder Returns
| IGMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.2% | -2.5% | 0.1% |
| 1Y | -3.9% | 3.1% | 26.1% |
Return vs Industry: IGMS underperformed the US Biotechs industry which returned 3.7% over the past year.
Return vs Market: IGMS underperformed the US Market which returned 27.3% over the past year.
Price Volatility
| IGMS volatility | |
|---|---|
| IGMS Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IGMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IGMS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 198 | Mary Harler | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
| IGMS fundamental statistics | |
|---|---|
| Market cap | US$440.03m |
| Earnings (TTM) | -US$219.84m |
| Revenue (TTM) | US$2.92m |
152.4x
P/S Ratio-2.0x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGMS income statement (TTM) | |
|---|---|
| Revenue | US$2.92m |
| Cost of Revenue | US$184.38m |
| Gross Profit | -US$181.46m |
| Other Expenses | US$38.38m |
| Earnings | -US$219.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.70 |
| Gross Margin | -6,218.71% |
| Net Profit Margin | -7,534.03% |
| Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 03:05 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IGM Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |